智通财经APP讯，昊海生物科技(06826)发布公告，于2025年9月18日该公司斥资64.92万港元回购2.35万 股，回购价格为每股27.60-27.72港元。 ...

FF305 第 1 頁 共 7 頁 v 1.3.0 呈交日期： 2025年9月18日 | 1). | 於 2025 年9月15日回購股份但尚未註銷 | | 67,400 | % | HKD | 27.78 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年9月15日 | | | | | | 2). | 於 2025 年9月16日回購股份但尚未註銷 | | 10,000 | % | HKD | 27.68 | | | 變動日期 | 2025年9月16日 | | | | | | 3). | 於 2025 年9月17日回購股份但尚未註銷 | | 18,400 | % | HKD | 28 | | | 變動日期 | 2025年9月17日 | | | | | | 4). | 於 2025 年9月18日回購股份但尚未註銷 | | 23,500 | 0.0103 % | HKD | 27.63 | | | 變動日期 | 2025年9月18日 | | | | | | 2. 股份分類 | 普通股 | A 股份類別 | | 於香港聯交所上市 | 否 | | ...

登录新浪财经APP 搜索【信披】查看更多考评等级 来源：环球网 【环球网财经综合报道】9月17日，昊海生科（688366.SH）公告称，公司控股股东、实际控制人之一 蒋伟于今年5月收到中国证监会出具的《立案告知书》，因涉嫌内幕交易被立案调查。昊海生科表示， 该事项仅涉及蒋伟个人，与公司无关，且蒋伟不参与公司日常经营管理，因此不会对公司的日常经营、 业务及财务造成重大影响。公司称，最终行政处罚结果将以中国证监会对蒋伟出具的《行政处罚决定 书》为准，并将持续关注事项进展，及时履行信息披露义务。 （图片来 源：上市公司公告） 公开资料显示，昊海生科业务覆盖玻尿酸、表皮修复基因工程制剂、射频及激光设备四大品类，产品应 用于医疗美容、生活美容及家用美容三大场景。 公司2024年半年度报告显示，受多个产品线主营业务收入减少影响，上半年业绩出现下滑。期内实现营 业收入130,440.28万元，同比下降7.12%；主营业务收入为129,755.17万元，同比减少7.52%。从细分业 务来看，医疗美容与创面护理产品收入57,544.98万元，同比下降9.31%；眼科产品收入36,754.10万元， 降幅达18.61%；骨科产品 ...

Summary of Key Points Core Viewpoint - On September 17, 28 Hong Kong-listed companies conducted share buybacks, totaling 16.7684 million shares and an aggregate amount of HKD 649 million [1][2]. Group 1: Share Buyback Details - Tencent Holdings repurchased 839,000 shares for HKD 551 million, with a highest price of HKD 663.50 and a lowest price of HKD 645.50, bringing its total buyback amount for the year to HKD 52.707 billion [1][2]. - Hang Seng Bank repurchased 200,000 shares for HKD 23.8014 million, with a highest price of HKD 119.30 and a lowest price of HKD 118.40, totaling HKD 793 million in buybacks for the year [1][2]. - Pacific Shipping repurchased 6 million shares for HKD 14.9526 million, with a highest price of HKD 2.52 and a lowest price of HKD 2.45, accumulating HKD 203 million in buybacks for the year [1][2]. Group 2: Ranking of Buybacks - The highest buyback amount on September 17 was from Tencent Holdings at HKD 551 million, followed by Hang Seng Bank at HKD 23.8014 million [1][2]. - In terms of share quantity, Pacific Shipping led with 6 million shares repurchased, followed by Linklogis Technology and Weigao Group with 2.3 million and 1.9548 million shares, respectively [1][2]. Group 3: Additional Buyback Information - Other notable companies involved in buybacks include Weigao Group, MGM China, and Jitu Express, with respective buyback amounts of HKD 11.4255 million, HKD 7.873 million, and HKD 7.8348 million [2][3]. - The buyback activity reflects a strategic move by these companies to enhance shareholder value amid market conditions [1][2].

Summary of Key Points Core Viewpoint - Multiple companies, including Tencent Holdings and Hang Seng Bank, conducted share buybacks on September 17, 2025, with Tencent leading in both the number of shares repurchased and the total amount spent. Group 1: Company Buyback Details - Tencent Holdings (00700) repurchased 839,000 shares for a total of 551 million, with a year-to-date total of 58.158 million shares, representing 0.633% of its total share capital [1][2] - Hang Seng Bank (00011) repurchased 200,000 shares for 23.8014 million, with a year-to-date total of 6.93 million shares, representing 0.368% of its total share capital [2] - Pacific Shipping (02343) repurchased 6 million shares for 14.9526 million, with a year-to-date total of 41.006 million shares, representing 0.798% of its total share capital [2] - Weigao Group (01066) repurchased 1.9548 million shares for 11.4255 million, with a year-to-date total of 14.2136 million shares, representing 3.148% of its total share capital [2] - MGM China (02282) repurchased 502,000 shares for 7.873 million, with a year-to-date total of 2.23295 million shares, representing 0.587% of its total share capital [2] Group 2: Other Notable Buybacks - Jitu Express-W (01519) repurchased 870,000 shares for 7.8348 million, with a year-to-date total of 870,000 shares, representing 0.010% of its total share capital [2] - Linkage Technology-W (09959) repurchased 2.3 million shares for 7.4586 million, with a year-to-date total of 19.9075 million shares, representing 0.932% of its total share capital [2] - Mengniu Dairy (02319) repurchased 200,000 shares for 3.074 million, with a year-to-date total of 10.816 million shares, representing 0.276% of its total share capital [2] - China Hongqiao (01378) repurchased 112,500 shares for 2.822 million, with a year-to-date total of 150 million shares, representing 1.610% of its total share capital [2] - Coolpad Group (02369) repurchased 1.348 million shares for 1.8057 million, with a year-to-date total of 23.095 million shares, representing 5.639% of its total share capital [2]

Core Viewpoint - The core issue revolves around Jiang Wei, a significant shareholder and actual controller of Hyaluronic Acid giant Haohai Biological Technology, receiving a notice of administrative penalty from the China Securities Regulatory Commission for suspected insider trading. The company asserts that the matter is unrelated to its operations and is solely a personal issue concerning Jiang Wei [1]. Company Summary - Haohai Biological Technology announced that Jiang Wei, one of its major shareholders and actual controllers, has been penalized by the China Securities Regulatory Commission for alleged insider trading [1]. - The company emphasized that the penalty pertains to Jiang Wei as an individual and does not involve the company itself [1]. - Although Jiang Wei founded Haohai Biological Technology, he has largely remained behind the scenes and does not actively participate in the company's operations [1]. - Jiang Wei has established a shareholding structure that allows him to maintain control over Haohai Biological Technology, and he has received over 250 million yuan in dividends from the company during its six years as a publicly listed entity [1]. Industry Context - The incident highlights the ongoing scrutiny of insider trading practices within the biotechnology sector in China, particularly among companies with significant market presence like Haohai Biological Technology [1]. - The company's chairman, Hou Yongtai, previously stated that Jiang Wei is primarily an investor who enjoys trading stocks, but he does not engage in trading Haohai Biological Technology's shares [1].

Core Viewpoint - The announcement regarding the insider trading investigation of Jiang Wei, a major shareholder and actual controller of Haohai Biological Technology Co., Ltd., has raised concerns among investors about the company's future, despite the company's claims that the incident is unrelated to its operations [1][2]. Group 1: Company Background - Haohai Biological Technology was founded in 2007 and has evolved into a technology-driven enterprise engaged in the research, production, and sales of medical devices and pharmaceuticals, focusing on aesthetic medicine and wound care, ophthalmology, and orthopedic products [5]. - The company was listed on the Hong Kong Stock Exchange in April 2015 and later on the Shanghai Stock Exchange's Sci-Tech Innovation Board in October 2019 [5]. Group 2: Shareholder Structure - Jiang Wei and You Jie are the controlling shareholders, holding 28.53% and 17.29% of the shares, respectively, making them the first and second largest shareholders [3]. - Jiang Wei is also the ultimate beneficiary of a partnership that holds 1% of the company's shares, indicating a significant influence over the company's governance [3]. Group 3: Financial Performance - In 2024, Haohai Biological reported revenue of 2.698 billion yuan, a mere 1.64% increase compared to previous years, indicating a significant slowdown in growth [5]. - The company experienced a decline in revenue and net profit in the first half of 2025, with revenue dropping by 7.12% to 1.304 billion yuan and net profit decreasing by 10.29% to 211 million yuan [6]. - The three main business segments—medical aesthetics, ophthalmology, and orthopedics—saw revenue declines of 9.31%, 18.61%, and 2.58%, respectively, in the first half of 2025 [6]. Group 4: Management and Strategy - The company's operational management is handled by a professional team led by key figures such as Hou Yongtai and Wu Jianying, who hold significant positions within the company [3]. - The company has reported a 21.53% decrease in R&D expenses, with the R&D expense ratio falling to 7.54% from 8.93% in the previous year, attributed to the completion of core projects [6].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年9月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 ...

智通财经APP讯，昊海生物科技(06826)发布公告，于2025年9月17日，该公司斥资51.52万港元回购1.84 万股。 ...

昊海生物科技(06826)发布公告，于2025年9月17日，该公司斥资51.52万港元回购1.84万股。 ...